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Abstract:  
. 
 
The spread of SARS-CoV-2 in Africa is poorly described. The first case of SARS-CoV-2 in 
Kenya was reported on March 12, 2020 and an overwhelming number of cases and deaths were 5 
expected but by July 31, 2020 there were only 20,636 cases and 341 deaths. However, the extent 
of SARS-CoV-2 exposure in the community remains unknown. We determined the prevalence of 
anti-SARS-CoV-2 IgG among blood donors in Kenya in April-June 2020. Crude seroprevalence 
was 5.6% (174/3098). Population-weighted, test-performance-adjusted national seroprevalence 
was 4.3% (95% CI 2.9–5.8%) and was highest in urban counties, Mombasa (8.0%), Nairobi 10 
(7.3%) and Kisumu (5.5%). SARS-CoV-2 exposure is more extensive than indicated by case-
based surveillance and these results will help guide the pandemic response in Kenya, and across 
Africa. 
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Main Text:  
Africa accounts for 17% of the global population (1) but by late July 2020 accounted for only 
5% of the global COVID-19 cases and 3% of global COVID-19 deaths reported (2). This 
disparity has been attributed to limited capacity for diagnosis, timely implementation of stringent 5 
containment measures, a younger population structure and a predominance of asymptomatic and 
mild infections (3, 4). The first case of COVID-19 in Kenya was detected on March 12, 2020. 
Within one week the government instituted containment measures to limit the spread of the virus 
(5). By July 31, national surveillance recorded 20,636 cases and 341 deaths (6). This increase in 
cases is notably slower than the epidemic in Wuhan, Europe or the USA. Recently, it has been 10 
suggested that “the virus is spreading… …with an attenuated outcome in Africa” but there are 
few data available to confirm or refute this assertion (7). 
In countries affected early in the pandemic, serological surveillance was used to define 
cumulative incidence. For example, at the release of lockdown in Wuhan, 9.6% of staff resuming 
work were found to have anti-SARS-CoV-2 antibodies (8). At the end of the epidemic wave in 15 
Spain, seropositivity was 5.0% in a random population sample of 60,897 (9). As the epidemic 
curve declined in Geneva, seroprevalence rose over three weeks from 4.8% to 10.9% (10). 
Currently, there are few estimates of SARS-CoV-2 seroprevalence in Africa in the literature 
(11). 
Movement restrictions, in response to COVID-19, have limited the conduct of fieldwork for 20 
population-based serosurveys. Several countries have monitored seroprevalence in blood 
transfusion donors (12, 13) or expectant mothers attending ante-natal clinics (14). Here we report 
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the results of a pragmatic national serosurvey using residual blood samples from transfusion 
donors across Kenya and a highly sensitive and specific assay for anti-SARS-CoV-2 spike 
immunoglobulin G (IgG). 
We validated a widely-used enzyme linked-immunosorbent assay for SARS-CoV-2 IgG (15) 
with 910 serum samples from the pre-pandemic period and 174 sera from polymerase chain 5 
reaction (PCR) defined SARS-CoV-2 cases, and a well-characterized 5 sera panel from the 
National Institute of Biological Standards and Control (NIBSC) in the UK. For either receptor-
binding domain (RBD) or whole spike, specificity was higher when using a ratio of the sample 
optical density (OD)/negative control OD than when using the raw sample OD plus 3 standard 
deviations to define seropositivity (Table S1). By using OD ratios, both RBD and spike ELISAs 10 
correctly classified 901 of 910 pre-pandemic samples as seronegative (Table S1). However, the 
spike ELISA detected more seropositives (166 of 179 vs compared to 145 of 179 for RBD 
ELISA) among sera from SARS-CoV-2 PCR-positive individuals (Figure S2, panels A & B). 
Based on these data, we defined anti-SARS-CoV-2 IgG seropositivity as an OD ratio >2 and 
selected the spike ELISA for this study. The sensitivity and specificity, at this threshold, were 15 
92.7% (95% CI 87.9-96.1%) and 99.0% (95% CI 98.1-99.5%), respectively (Table S1, Figure S3 
panels A & B, Figure S5 and S6). As previously noted (15), the RBD and whole spike ELISA 
responses were highly correlated (Figure S3, panel C), with very little inter-assay variation 
(Figure S4). 
A total of 3,174 blood transfusion samples were collected from four Kenya National Blood 20 
Transfusion Service (KNBTS) regional blood transfusion centers that are supported by several 
satellites and hospitals between April 30 and June 16, 2020, from individuals aged 15-66 years. 
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Approximately half of the samples were drawn in Mombasa; the remainder were evenly 
distributed between Nairobi, Kisumu and Eldoret (Figure 1, Table S2). We excluded 18 duplicate 
samples, 56 records missing data on age or collection date and two records from individuals aged 
≥65 years. Policy in Kenya is to avoid blood donation from individuals >65 years, and we 
excluded these other data points as potentially unreliable.  These exclusions left 3,098 samples 5 
for further analysis (Figure 1). 
Of the 3,098 samples, 174 were positive for anti-SARS-CoV-2 Spike IgG giving a crude 
seroprevalence of 5.6% (95% CI 4.8–6.5%). Crude seroprevalence varied by age (p=0.046), 
ranging between 3.4-7.0% among adults 15-54 years; all 71 donors aged 55-64 years were 
seronegative (Table 1). Crude seroprevalence did not vary by sex (p=0.50) but did vary 10 
geographically, from 1.9% in the Rift Valley region to 10.0% in the Western region (p=0.002, 
Table 1). 
Compared to the 2019 Kenya Population and Housing Census, our participants were more 
commonly male (82.0% in our study vs 49.3% in the census), had more persons aged 25-34 
years (40.1% vs 27.3%) and more residents of coastal Counties (49.2% versus 9.1%, Table 2). 15 
We therefore adjusted the prevalence estimate for the demographics of the sample using post-
stratification, and for the sensitivity and specificity of the test. 
The Bayesian population-weighted and test-adjusted seroprevalence for Kenya was 4.3% (95% 
CI 2.9-5.8%, Table 1) and the posterior sensitivity and specificity estimates were 92.4% (95% CI 
88.0-95.6%) and 98.9 (95% CI 98.2-99.5%), respectively. Seroprevalence was higher (4.2-5.2%) 20 
in the younger age groups (15-44 years) and declined in the older age groups (45-64 years) but 
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was similar for both sexes. Seroprevalence was highest for those living in Mombasa, Nairobi and 
the Western region, although the number of observations for the Western region was small. The 
directly standardized seroprevalence estimates are presented in Table S3. Seroprevalence was 
also calculated for Counties that had at least 120 donors sampled. The three largest urban 
Counties of Mombasa, Nairobi, and Kisumu had SARS-CoV-2 seroprevalence of 8.0% (95% CI 5 
5.5-11.1%), 7.3% (95% CI 4.2-11.4%) and 5.5% (95% CI 2.8-9.6%), respectively (Table S4).  
The frequency of blood donor sampling and crude seroprevalence estimates increased with time 
over the 7-week study period (Figure 2). The median sample date was May 30, 2020 while the 
mid-point of the study was May 24, 2020. We did not adjust for sample date because the period 
of sampling varied for residents of different counties (Figure 2C); instead we show the variation 10 
in crude prevalence over time (Figure 2A). 
Voluntary non-remunerated donors (VNRDs), who donate blood at community-based ‘blood 
drives’ comprised only 7.6% (236/3098) of our sample of donors; the remainder were family 
replacement donors (FRDs) who provide a unit of blood in compensation for a transfusion 
received by a sick relative. The two groups did not differ significantly by age (p=0.15) or sex 15 
(p=0.51, Table S5). Crude seroprevalence was 8.5% (20/236) for VNRDs and 5.4% (154/2862) 
for FRDs. The median sample date for VNRDs (June 14, 2020) was two weeks later than that for 
FRDs (May 29, 2020). 
Population exposure across Kenya, with a population-weighted test-adjusted seroprevalence of 
4.3%, is considerably higher than was previously thought, based on the cases and deaths reported 20 
to date. Seroprevalence was particularly high in the three urban counties; Mombasa (8.0%), 
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Nairobi (7.3%) and Kisumu (5.5%). Consistent with other studies, seroprevalence did not vary 
significantly by sex; (9, 10, 16) however, it peaked in 35-44-year-olds and was lowest for those 
≥45 years, which is also consistent with existing reports where seroprevalence was found to be 
lower in older adults (9, 10).  
SARS-CoV-2 seroprevalence in our study is comparable to estimates from large population-5 
based serosurveys in China, Switzerland, Spain and the USA after the initial epidemic peak and 
following many tens of thousands of deaths (9, 10, 17, 18). Our results are also comparable to 
other surveys of blood donors in Brazil (13), Italy (12), and many parts of England (19). Kenya 
has an estimated population of 53 million in 2020 and 57% of the population is aged 15-64 years. 
If the transfusion donor seroprevalence of 4.3% was applied to all 15-64-year-olds it would 10 
suggest approximately 1.3 million infections. However, by the median sample date, May 30, 
2020, only 2093 cases had been detected (of which approximately 90% were asymptomatic) and 
71 deaths among all ages (6). Although it is difficult to extrapolate our data directly to the whole 
population, they do strongly suggest that the infection is more widespread in Kenya than the 
current PCR test results suggest and indicate a need for more systematic testing. The current 15 
PCR testing strategy targets symptomatic individuals, health care workers, contacts of confirmed 
cases, international travelers, cross border truck drivers and residents of areas identified as hot 
spots.” 
What are the potential explanations for the divergence in the ratio of observed cases or deaths to 
serologically defined infections inferred from transfusion donors in Kenya, compared to many 20 
high-income countries? (i) The seroprevalence could be over-estimated because of bias in the 
selection or behavior of blood transfusion donors. (ii) Cases could be under-ascertained by 
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national public health surveillance though it seems unlikely that reporting of deaths and severe 
cases could be reduced by several orders of magnitude, and hospitals in Kenya were not 
overwhelmed by admissions with respiratory illness. (iii) The steep demographic age-pyramid 
results in a smaller vulnerable age group. In Kenya, only 3.9% of the population is aged 65 years 
or greater which is substantially less than, for example, 23.3% found in Italy; again, this would 5 
only explain a several-fold reduction in severe cases or deaths (4). (iv) There may be alternative 
mechanisms of immunity to SARS-CoV-2 including cell-mediated immunity (20, 21) perhaps as 
a result of HCoV-elicited immunity (22, 23). Despite our prior work showing HCoVs circulate in 
Kenya (24), we did not identify evidence of cross-reactive antibodies to endemic coronaviruses 
in our validation study.  10 
Although blood donors are not representative of the Kenyan population as a whole, we adjusted 
for demographic bias in the sample structure by standardization against the age, sex, and regional 
distribution of the Kenyan population. A substantial proportion (43%) of the population of 
Kenya is outside the age-range (15-64 years) sampled in this study and the seroprevalence in 
children <15 years and adults >65 years is often lower (9, 10); our estimate for blood donors may 15 
be higher than the estimate for the population as a whole. Blood donors also differ from the 
general population in their risk of exposure to SARS-CoV-2. For instance, potential donors are 
excluded from giving blood if they have been ill during the last six months so the sample may 
underestimate the population prevalence of SARS-CoV-2 antibodies; on the other hand, people 
who are shielding at home are unlikely to be captured in our sample leading to an overestimate 20 
of seroprevalence. Our exploration of the two distinct populations of blood donors, FRDs and 
VNRDs, suggests variation in the seroprevalence by donor group but, of note, 92% (2862/3098) 
of our sample came from the group with lower seroprevalence and exclusion of VNRDs reduced 
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the crude seroprevalence in our study little, from 5.6% to 5.4%. Against these considerations, 
other countries have relied on blood transfusion donors for an early estimate of seroprevalence 
but later estimates from random population samples have not been substantially different (25, 
26). 
A key strength of this study is the rigorous validation that included testing positive and negative 5 
control samples from the target population, as well as reference plasma from the UK NIBSC as 
part of a WHO-coordinated effort on SARS-CoV-2 seroepidemiology. In addition, we adopted a 
conservative seropositivity threshold to optimize assay specificity and sensitivity for our setting. 
The pandemic response in countries with limited health care capacity has been driven by the 
aggressive implementation of control measures to limit transmission. Unfortunately, this strategy 10 
has been accompanied by enormous collateral costs, particularly in Africa. Modelled estimates of 
the disruptions of essential medical services, such as immunization and antenatal care, suggest an 
additional ~253,500 child deaths and 12,200 maternal deaths over six months in low and middle-
income countries (27). In the absence of social protection, the economic effects of lockdown are 
debilitating so it is important to obtain an early measure of the trajectory of the epidemic. 15 
Our study provides a national and regional estimate of population exposure to SARS-CoV-2 in 
an African country. The 4.3% prevalence in blood transfusion donors is in sharp contrast with 
the reported COVID-19 cases and deaths and supports the impression that disease may be 
attenuated in Africa (7). 
  20 
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Figures 
Figure 1. Participant flow diagram for SARS-CoV-2 seroprevalence study of blood donors 
in Kenya. Exclusion criteria for the selection of samples with complete data. 
 
 5 
Figure 2. Timeline of sampling for SARS-CoV-2 seroprevalence in blood donors in Kenya. 
Against the timeline of the sampling period, panel A shows the weekly crude seroprevalence and 
95% confidence interval, panel B shows the daily frequency of samples collected and panel C 
shows the temporal distribution of samples by region. Proportion, counts and regional 
distribution of donors during the study period.  10 
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Table 1. Crude, population-weighted, and test performance-adjusted SARS-CoV-2 anti-spike protein IgG seroprevalence by 
participant characteristics and regions.  Prevalence estimates calculated using multilevel regression and post-stratification (MLRP) 
to account for differences in the sample population and the national population, subsequently adjusted for assay sensitivity and 
specificity. 
 5 
 
All samples 
Seropositive 
samples Crude seroprevalence 
Kenya population 
(2019 Census) 
Bayesian population-weighted 
seroprevalence* 
Bayesian population-weighted, 
test-adjusted seroprevalence* 
   % (95% CI)  % (95% CI) % (95% CI) 
Age          
15 – 24 years 808 49 6.1 4.5 – 7.9 9,733,174 5.1 3.7 – 6.9 4.4 2.7 – 6.4 
25 – 34years 1242 66 5.3 4.1 – 6.7 7,424,967 4.9 3.6 – 6.4 4.2 2.8 – 6.0 
35 – 44 years 714 50 7.0 5.2 – 9.1 4,909,191 5.9 4.3 – 8.1 5.2 3.3 – 7.7 
45 – 54 years 263 9 3.4 1.6 – 6.4 3,094,771 3.8 1.9 – 6.0 3.0 1.1 – 5.4 
55 – 64 years 71 0 0  1,988,062 3.4 0.7 – 6.2 2.9 0.7 – 5.7 
          
Sex          
Male 2540 146 5.7 4.9 – 6.7 13,388,243 4.4 2.9 – 6.2 3.6 1.9 – 5.8 
Female 558 28 5.0 3.4 – 7.2 13,761,922 5.5 4.4 – 6.8 4.8 3.5 – 6.4 
          
Regions          
Central 105 7 6.7 2.7 – 13.2  3,452,213 5.6 2.9 – 10.0 4.9 1.9 – 9.7 
Mombasa 550 51 9.3 7.0 – 12.0 792,072 8.3 6.1 – 10.9 7.8 5.4 – 10.8 
Other Coast 973 39 4.0 2.9 – 5.4 1,671,097 3.7 2.6 – 5.1 2.9 1.6 – 4.6 
Eastern / N. Eastern 242 11 4.5 2.3 – 8.0 5,176,080 4.3 2.5 – 7.0 3.5 1.4 – 6.6 
Nairobi 235 21 8.9 5.6 – 13.3 3,002,314 7.6 4.9 – 11.2 7.1 4.2 – 11.2 
Nyanza 442 30 6.8 4.6 – 9.5 3,363,813 6.0 4.2 – 8.4 5.2 3.1 – 7.9 
Rift Valley 481 8 1.7 0.7 – 3.3 7,035,581 2.1 1.1 – 3.6 1.5 0.4 – 3.1 
Western 70 7 10.0 4.1 – 19.5 2,656,995 7.0 3.5 – 13.1 6.3 2.5 – 13.1 
          
Total 3,098 174 5.6 4.8 – 6.5 27,150,165 4.9 3.9 – 6.2 4.3 2.9 – 5.8 
 *Re-weighted prevalence estimates based on demographic data from the 2019 Kenya Population and Housing Census
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Table 2. General characteristics of the study population compared to the national 
population of Kenya. N is the number of individuals in each stratum. 
 
  Blood transfusion samples Kenya National Census 2019 
  N % N % 
      
Age 15-24 years 808 26.1 9,733,174 35.8 
 25-34 years 1,242 40.1 7,424,967 27.3 
 35-44 years 714 23.0 4,909,191 18.1 
 45-54 years 263 8.5 3,094,771 11.4 
 55-64 years 71 2.3 1,988,062 7.3 
      
Sex Male 2540 82.0 13,388,243 49.3 
 Female 558 18.0 13,761,922 50.7 
      
Regions Central 105 3.4 3,452,213  12.7 
 Mombasa 550 17.8 792,072  2.9 
 Other Coast 973 31.4 1,671,097  6.2 
 Eastern / N. Eastern 242 7.8 5,176,080  19.1 
 Nairobi 235 7.6 3,002,314  11.1 
 Nyanza 442 14.3 3,363,813  12.4 
 Rift Valley 481 15.5 7,035,581  25.9 
  Western 70 2.3 2,656,995  9.8 
      
Total Kenya 15-64 years 3098  27,150,165  
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Materials and Methods 
Study sample 
This study was carried out at the KEMRI-Wellcome Trust Research Programme 
(KWTRP) in Kilifi, Kenya, in collaboration with the Kenya National Blood Transfusion 
Service (KNBTS). The KWTRP is the government-designated laboratory for SARS-CoV-
2 testing in Coastal Kenya. 
Anonymized residual donor serum samples, used for screening of transfusion 
transmissible infections, were collected at 4 KNBTS regional centers (Mombasa, Nairobi, 
Eldoret and Kisumu). The KNBTS guidelines (28) define eligible blood donors as 
individuals aged 16-65 years, weighing ≥50kg, with hemoglobin of 12.5g/dl, a normal 
blood pressure (systolic 120–129 mmHg and diastolic BP of 80–89 mmHg), a pulse rate 
of 60-100 beats per minute and without any history of illness in the past 6 months. KNBTS 
normally relies on voluntary non-remunerated donors (VNRD) recruited at public blood 
drives typically located in high schools, colleges and universities. Since September 2019, 
because of reduced funding, KNBTS has depended increasingly on family replacement 
donors (FRD) who provide units of blood in compensation for those received by sick 
relatives. Family replacement donors are close family members or friends within 
immediate reach willing to assist the patient.  
Although we sampled from only 4 of 6 regional centers, the sample provides a much wider 
national representation because each regional center serves between 5-10 administrative 
counties. Supplementary Table S2 shows the distribution of the donors from the four 
regional blood transfusion centers across hospitals and satellite blood banks in the various 
administrative counties. Patients at health facilities served by the regional centers typically 
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would have travelled some distance to obtain secondary and tertiary care, including 
transfusion, and relatives, acting as FRDs, may be called in from farther afield. Movement 
restrictions in/out of Nairobi and Mombasa Counties to control the transmission of 
COVID-19 reduced, but did not completely exclude, this wider representation.  
Assuming a COVID-19 seroprevalence ranging from 3-10% during the study duration, a 
sample of 300-500 blood donors per operations center per month will give a 4-7% margin 
of error for seroprevalence estimates. 
Antibody testing using SARS-CoV-2 Spike Protein ELISA 
We adapted the Krammer Enzyme linked Immunosorbent assay  as follows (15): Nunc 
MaxiSorp™ flat-bottom 96-well plates (ThermoFisherScientific) were coated with 
2µg/ml of whole trimeric spike protein or spike receptor binding domain  (RBD) (Figure 
S1) at 37°C for 1h, washed 3 times in wash buffer (0.1% Tween 20 in 1X phosphate 
buffered saline) and blocked with Blocker™ Casein (ThermoFisherScientific) for 1h at 
room temperature. Heat-inactivated serum or plasma samples were diluted 1:800 in 
Blocker™ Casein, added to the spike- or RBD-coated plates and incubated for 2h at room 
temperature. After 3 further washes, 100µl horseradish peroxidase-conjugated goat anti-
human IgG antibody (Catalogue number 074-1002, KPL-SeraCare), diluted 1:10,000 in 
wash buffer, was added to the plates. They were incubated for 1h at room temperature, 
washed 3 times and developed with o-phenylenediamine dihydrochloride (OPD) substrate 
(Sigma) for 10 min. Plates were read on an Infinite® 200 PRO microplate reader 
(TECAN) at 492 nm. The CR3022 monoclonal antibody (mAb) was used as positive 
control. A pool of sera from 50 adults sampled pre-COVID-19 pandemic was used as 
negative control. 
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ELISA performance, validation and definition of a threshold for seropositivity 
We validated the RBD and whole trimeric spike ELISAs against panels of pre-pandemic 
and pandemic serum/plasma (Table S1). The gold-standard negative ‘pre-pandemic’ 
serum/plasma panels comprised: sera from annual cross-sectional surveys for malaria 
surveillance in coastal Kenya in April-May 2018 (200 adults and 200 children); (2) sera 
from 500 adult blood donors collected in 2018 as part of research into the quality of 
transfused blood in coastal Kenya; (3) convalescent plasma from children (n=9) admitted 
to Kilifi County Hospital 2011-2013 with PCR-confirmed infection with endemic human 
coronavirus NL63 (n=4) or OC43 (n=5) (24).   
The gold-standard positive ‘pandemic’ plasma panel comprised plasma from 174 COVID-
19 patients sampled ≥7 days after their PCR-positive diagnosis (Figure S2), and a well-
characterized panel of 5 plasma samples from the National Institute of Biological 
Standards and Control (NIBSC) in the UK. These included the research reagent for anti-
SARS-CoV-2 Ab (NIBSC code 20/130), and the convalescent plasma panel NIBSC code 
20/118 that includes a panel of 4 convalescent plasma from recovered COVID-19 patients 
in the UK and a pre-pandemic plasma pool from healthy UK adults.  
Assay performance was assessed by testing these serum/plasma panels against both the 
RBD and whole trimeric spike protein of SARS-CoV-2 by IgG ELISA. Both assays had 
the same performance characteristics in our hands and, as the specificity of either was 
already excellent, in the interests of laboratory efficiency, we chose to pursue our studies 
with one assay alone. We chose the assay with the highest sensitivity. CR3022 mAb was 
used as positive control and a pool of pre-pandemic sera from 50 Kenyan adults was used 
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as a negative control. These were randomly selected from the malaria cross-sectional 
surveillance samples described earlier. 
Ethical Considerations 
This study was approved by the Scientific and Ethics Review Unit (SERU) of the Kenya 
Medical Research Institute (Protocol SSC 3426). Before the blood draw, donors gave 
individual consent the use of their samples for research. Ethical approval was obtained for 
collection, storage and further use for the sample sets used in the validation assays (SERU 
numbers: 1433, 3149, 3426). 
Statistical Analysis 
We tabulated seropositive results by age, sex and residence (county or region). Because 
the survey was a non-random sample of the Kenyan population, we also calculated 
standardized prevalence estimates using population data from the Kenya 2019 census. We 
used 2 methods of standardization; 1) direct standardization on the observed prevalence 
and population weights in 80 region-age-sex strata, and 2) multilevel regression and post-
stratification (MLRP) adjusted for the sensitivity and specificity of the assay (29). To 
predict stratum prevalence for MLRP we fitted a Bayesian logistic regression model that 
included sex as a fixed effect, and age and region as random effects (30). The Bayesian 
analysis was done using the rjags package in R version 3.6.1.(31). We used vague or 
weakly informative priors for all parameters (30). 
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We plotted sample distribution and seroprevalence over time to illustrate potential time-
trends and tabulated seroprevalence across different donor groups (FRDs vs VNRDs) to 
explore potential biases. 
Multilevel regression and post-stratification (MRP) was used to reweight the regional, 
age-specific and sex-specific prevalence estimates. The method was implemented in 2 
stages: 
 
1) A hierarchical regression model was used to predict the prevalence in 80 age-sex-
region strata (5 categories of age, 8 regions and 2 categories of sex) 
 
2) Regional, age-specific and sex-specific prevalence estimates were obtained by 
appropriately weighting stratum-specific prevalence estimates using data from the 2019 
Kenyan census. For example, to estimate the prevalence in Mombasa, the age and sex 
specific prevalence estimates for the Mombasa were weighted by age and sex specific 
population totals.  
 
In the hierarchical model, the number of seropositive individuals in age group (! =
1,…5), region (( = 1,… ,8) and sex (* = 1, 2)	follows a binomial distribution: 
 
-!"# 	~	Bin(3!"# , 4!"#∗ ). 
 
where  4!"#∗ 	is the observed prevalence and 3!"# 	is the number tested.  
 
The observed prevalence depends on the true prevalence as well as the sensitivity and 
specificity of the assay, i.e. 
4!"#∗ = 4!"# × 67 + (1 − 4!"#) × (1 − 64). 
 
And the true prevalence, 4!"# ,	 depends on age, region and sex according to the following 
logistic model: 
 
logit(4!"#) = >% + >&(* − 1) + (?" − ?̅) + (A! − AB) 
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?" 	~	NDE'()*+,, 	F'()*+,- G 
 
A! 	~	NDE.)(, 	F.)(- G. 
 
Note that ?" 	and A! are centred around their respective means. Although we could have 
fitted an equivalent uncentered model with ?" 	~	ND0, 	F'()*+,- G and A! 	~	ND0, 	F.)(- G, we 
chose instead to centre these variables to reduce autocorrelation in the McMC-generated 
sample of the posterior distribution [Chapter 19 in Gelman and Hill] (29). 
 
To estimate 67 and 64 , we used data from 179 true positives (positive on PCR for 
SARS-CoV-2) and 910 true negatives (samples collected pre COVID-19). Among the 
true positives I = 166 tested positive on the assay, and among the true negatives J =
901 tested negative. These data were included in the likelihood by assuming a binomial 
model: I	~	Bin(67, 179	) and J	~	Bin(64, 910	).  
 
The full model was fitted using the following priors: 
 
>%	~	N(0, 10/) 
 
>&	~	N(0, 10/) 
 
logit(67)	~	N(1.5, 0.25) 
 
logit(64)	~	N(5.3, 0.25) 
 
	E.)(	~	N(0, 10/) 
 
E'()*+,	~	N(0, 10/) 
 
F.)(	~	N(0, 0.25)0 
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F'()*+,	~	N(0, 0.25)0. 
The half-normal priors for  F.)( and F'()*+, were chosen to be weakly informative (31). 
To interpret these priors, note that if the prevalence is 5% then a variance of 0.25 on the 
logit scale corresponds to 95% of estimates being between 1.9% and 12.5%. Non-
informative priors were used for all other parameters. 
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Rjags code: 
library(rjags) 
library(coda) 
 
### Data 
# female = 1, male = 2; 
# age categories: 1 = 15-24, 2 = 25-34, 3 = 35-44, 4 = 45-54, 5 = 55-64; 
# regions: 1 = central, 2 = coast_mombasa, 3 = coast_other, 4 = eastern/north eastern,  
# 5 = nairobi, 6 = nyanza, 7 = rift valley, 8 = western 
 
dat <- read.csv("stratum_level_data_prov7mom.csv") 
nr <- 8 
na <- 5 
ns <- 2 
y <- array(dat$spikepos, dim = c(na, nr, ns)) 
n <- array(dat$n, dim = c(na, nr, ns)) 
pw <- array(dat$pw, dim = c(na, nr, ns)) 
 
### Model  
 
model_string <- "model{ 
        
# Likelihood  
 
    for(i in 1:na){ 
      for(j in 1:nr){ 
        for(k in 1:ns){ 
        y[i, j, k] ~ dbinom(se * p[i, j, k]  + 
                            (1 - sp) * (1 - p[i, j, k]) , 
                            n[i, j, k]) 
     
        logit(p[i, j, k]) <- (b0 + b1 * (k - 1)  
                                + u[i] - mean(u[]) + v[j] - mean(v[]))  
    
        } 
      } 
    } 
 
# Sensitivity and specificity     
    
   x ~ dbinom(se, 179) 
   z ~ dbinom(sp, 910) 
     
# Age effect 
     
  tau_a <- 1/pow(sd_a, 2)   
  for(i in 1:na){ 
    u[i] ~ dnorm(mu_a, tau_a) 
    } 
    
# Region effect 
 
  tau_r <- 1/pow(sd_r, 2) 
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  for(j in 1:nr){ 
    v[j] ~ dnorm(mu_r, tau_r) 
    } 
  
# Priors 
   
  b0 ~ dnorm(0, 1e-04) 
  b1 ~ dnorm(0, 1e-04) 
  se ~ dunif(0,1) 
  sp ~ dunif(0,1) 
 
# Hyperpriors 
 
  sd_a ~ dnorm(0, 4) T(0,) 
  sd_r ~ dnorm(0, 4) T(0,) 
  mu_a ~ dnorm(0, 1e-04) 
  mu_r ~ dnorm(0, 1e-04) 
   
# Predicted prevalence by age, region and sex 
 
  for(i in 1:na){ 
    age[i] <- inprod(p[i,1:nr,1:ns], pw[i,1:nr,1:ns])/sum(pw[i,1:nr,1:ns]) 
  } 
 
  for(j in 1:nr){ 
    region[j] <- inprod(p[1:na,j,1:ns], pw[1:na,j,1:ns])/sum(pw[1:na,j,1:ns]) 
  } 
 
  for(k in 1:ns){ 
    sex[k] <- inprod(p[1:na,1:nr,k], pw[1:na,1:nr,k])/sum(pw[1:na,1:nr,k]) 
  } 
   
  national <- inprod(p[1:na,1:nr,1:ns], pw[1:na,1:nr,1:ns]) 
   
  }" 
 
### Compile and update 
 
model <- jags.model(textConnection(model_string),  
                    data = list(y = y,  
                                n = n,  
                                x = 166,  
                                z = 901,  
                                pw = pw, 
                                na = na, 
                                nr = nr, 
                                ns = ns),  
                    n.chains = 1, 
                    inits = list(.RNG.name = "base::Wichmann-Hill",  
                                 .RNG.seed = 999)) 
                     
update(model, 1000, progress.bar = "none") # Burn-in period = 1000 samples 
 
samp <- coda.samples(model,  
                     variable.names = c("age", "region", "sex", "national", 
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                                        "se", "sp"),  
                     n.iter = 10000,  
                     progress.bar = "none") 
summary(samp) 
 
 
Data: "stratum_level_data_prov7mom" 
 
sex region agecat pop n spikepos pw 
1 1 1 519959 12 2 0.01915123 
1 1 2 460999 15 0 0.0169796 
1 1 3 362528 5 0 0.0133527 
1 1 4 250703 1 0 0.00923394 
1 1 5 154353 1 0 0.00568516 
1 2 1 129100 29 3 0.00475504 
1 2 2 133665 40 2 0.00492317 
1 2 3 73755 29 3 0.00271656 
1 2 4 35204 13 1 0.00129664 
1 2 5 17586 3 0 0.00064773 
1 3 1 318515 23 0 0.0117316 
1 3 2 235979 52 1 0.00869162 
1 3 3 143652 25 0 0.00529102 
1 3 4 89621 5 0 0.00330094 
1 3 5 70401 1 0 0.00259302 
1 4 1 917709 12 0 0.03380123 
1 4 2 658336 21 2 0.02424796 
1 4 3 467552 14 3 0.01722096 
1 4 4 296313 4 0 0.01091386 
1 4 5 204280 1 0 0.00752408 
1 5 1 506240 12 0 0.01864593 
1 5 2 546839 19 1 0.02014128 
1 5 3 277879 7 0 0.01023489 
1 5 4 121945 4 0 0.0044915 
1 5 5 50945 2 0 0.00187642 
1 6 1 667485 50 7 0.02458493 
1 6 2 500100 32 1 0.01841978 
1 6 3 275937 21 0 0.01016336 
1 6 4 184347 1 0 0.0067899 
1 6 5 159604 2 0 0.00587856 
1 7 1 1338584 20 0 0.04930298 
1 7 2 1004252 45 0 0.0369888 
1 7 3 579433 19 0 0.02134179 
1 7 4 374981 3 0 0.01381137 
1 7 5 233322 0 0 0.00859376 
1 8 1 536628 5 2 0.01976518 
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1 8 2 346576 4 0 0.01276515 
1 8 3 223106 5 0 0.00821748 
1 8 4 162342 0 0 0.00597941 
1 8 5 131167 1 0 0.00483117 
2 1 1 502372 21 1 0.01850346 
2 1 2 435831 30 2 0.01605261 
2 1 3 361207 14 2 0.01330404 
2 1 4 253810 6 0 0.00934838 
2 1 5 150451 0 0 0.00554144 
2 2 1 111366 97 11 0.00410185 
2 2 2 131180 174 21 0.00483165 
2 2 3 87176 106 9 0.00321088 
2 2 4 50520 47 1 0.00186076 
2 2 5 22520 12 0 0.00082946 
2 3 1 310596 174 6 0.01143993 
2 3 2 203297 369 13 0.00748787 
2 3 3 140459 209 15 0.00517341 
2 3 4 96887 87 4 0.00356856 
2 3 5 61690 28 0 0.00227218 
2 4 1 995785 46 0 0.03667694 
2 4 2 639043 75 2 0.02353735 
2 4 3 481607 45 3 0.01773864 
2 4 4 312435 22 1 0.01150767 
2 4 5 203020 2 0 0.00747767 
2 5 1 408632 36 3 0.01505081 
2 5 2 532179 82 7 0.01960132 
2 5 3 321079 50 9 0.01182604 
2 5 4 166936 19 1 0.00614862 
2 5 5 69640 4 0 0.00256499 
2 6 1 613177 143 9 0.02258465 
2 6 2 391827 114 8 0.01443185 
2 6 3 282754 54 4 0.01041445 
2 6 4 162762 17 1 0.00599488 
2 6 5 125820 8 0 0.00463423 
2 7 1 1338739 113 4 0.04930869 
2 7 2 928186 151 3 0.03418712 
2 7 3 621283 96 1 0.02288321 
2 7 4 392358 29 0 0.0144514 
2 7 5 224443 5 0 0.00826673 
2 8 1 518287 15 1 0.01908965 
2 8 2 276678 19 3 0.01019066 
2 8 3 209784 15 1 0.0077268 
2 8 4 143607 5 0 0.00528936 
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2 8 5 108820 1 0 0.00400808 
 
Fig. S1. SARS-CoV-2 RBD and whole spike protein and CR3022 mAb production 
 
 
SDS-PAGE and Western blot images of SARS-CoV-2 whole spike and RBD protein, and 
CR3022 elutions are shown. Concentrated proteins were mixed with 5x protein loading 
buffer (National Diagnostics) at a ratio of 4:1, heated for 10 min at 100°C and protein 
integrity analyzed on 10% reducing SDS-PAGE gels made with ProtoGel Quick-cast 12% 
(National Diagnostics). Gels were run at 100 V for 2 hours and stained with InstantBlue 
(Expedeon) and destained in distilled water overnight. To check the specificity of 
expressed and purified proteins, gels were run for 100 V for 2 h and the unstained gels 
blotted on PVDF Western blotting membrane (Sigma) by semi-dry transfer using Pierce 
Power Blot Cassette (ThermoFisherScientific). After transfer, the blot was blocked for 1 
h in 5% skimmed milk (blocker) and incubated for 1 hour with anti-poly-Histidine-
peroxidase antibody (Sigma) in blocker at a ratio of 1:1000. The blot was washed 4x with 
0.1% Tween 20 (Sigma) in 1x Phosphate Buffered Saline (PBS) (Thermo Fisher 
Scientific) and developed with DAB substrate (Sigma) containing 30% H2O2 (Sigma). 
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Fig. S2. Relationship between antibody response and time since PCR diagnosis 
 
 
 
Each point represents one of 174 SARS-CoV-2 positive individuals from Kenya included 
in the ‘pandemic’ panel, stratified by whether they had asymptomatic or symptomatic 
infection. The spike ELISA OD ratios are shown with respect to the duration between the 
PCR positive result and the sampling date of the serum used in the ELISA. 
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Fig. S3. Anti-SARS-CoV-2 Spike IgG antibody ELISA performance characteristics 
 
 
 
 
The OD ratios from spike and RBD ELISAs are shown. Each point represents an 
individual, colour-coded by the sampling period i.e. pre-pandemic or pandemic. The 
number of samples in each group are summarized in Table S1.  
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 Fig. S4. Assay reproducibility 
 
We assessed reproducibility of the spike ELISA by examining the ODs and coefficient of 
variation for the negative and positive (CR3022) controls for all the test runs done during 
the screening of the blood donor samples. All negative control ODs were expected to be 
<0.2 and >3 for positive controls. Performance was as expected with little inter-assay 
variation.  
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Fig. S5. Receiver operating characteristic curve for anti-Spike ELISA 
 
 
 
 
We assessed the discrimination of the OD ratio of anti-Spike IgG in a ROC curve 
constructed using 910 true negative controls and 179 true positive controls (see Table 
S1). The assay discriminates well between the two populations and the selected 
threshold of 2.00 has a sensitivity of 92.7% and a specificity of 99.0% at the upper left-
hand corner of the ROC curve. 
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Fig. S6. Impact of threshold selection on population discrimination 
 
 
 
Figure shows reverse cumulative distribution curves to illustrate the dynamic range, 
distribution and discrimination of the anti-Spike IgG ELISA results (expressed as a ratio 
of test OD to negative control OD) among the true negative controls, true positive samples 
and the 2020 blood transfusion donors. 
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Table S1.  Assay validation, selection and definition of seropositivity for SARS-CoV-2 ELISA  
 
  Sample OD>Negative control  
OD + 3SD 
Sample OD-to-Negative control OD 
ratio >2 
 N RBD +ve Spike +ve Both +ve RBD +ve Spike +ve Both +ve 
Pre-pandemic panel (gold standard negatives)        
Adults, Kilifi cross-sectional survey, 2018 200 39 22 10 5 2 0 
Adults, coastal Kenya blood donors, 2018 500 26 56 10 2 5 0 
Children, Kilifi cross-sectional survey, 2018 200 40 12 7 2 2 1 
Children, HCoV (OC43, NL63) convalescent plasma, 
2011-13 
9 0 0 0 0 0 0 
NIBSC UK adults pooled plasma 1 1 0 0 0 0 0 
Pandemic panel (gold standard positives)        
NIBSC UK COVID-19 convalescent plasma 5 5 5 5 5 5 5 
SARS-CoV-2 PCR positive cohort 174 159 164 159 140 161 139 
 
OD- Optical Density  
SD- Standard Deviation 
NIBSC UK- National Institute of Biological Standards and Control, United Kingdom 
HCoV- Human coronaviruses; convalescent plasma from 4 children admitted with HCoV NL63 infection, and 5 with HCoV OC43 infection. 
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Table S2. Distribution of blood donors across the various administrative regions in 
the country covered by the four regional blood centers.  
 
County Mombasa Nairobi Kisumu Eldoret Total 
Kilifi 485 0 0 0 485 
Kwale 236 0 0 0 236 
Lamu 82 0 0 0 82 
Mombasa 550 0 0 0 550 
Taita Taveta 133 0 0 0 133 
Tana River 37 0 0 0 37 
Garissa 0 3 0 0 3 
Kiambu 0 25 0 0 25 
Kitui 0 5 0 0 5 
Machakos 0 145 0 0 145 
Makueni 0 41 0 0 41 
Marsabit 0 11 0 0 11 
Nairobi 0 235 0 0 235 
Nyeri 0 80 0 0 80 
Turkana 0 15 0 26 41 
Wajir 0 37 0 0 37 
Bungoma 0 0 1 19 20 
Busia 0 0 23 0 23 
Homabay 0 0 56 0 56 
Kericho 0 0 1 0 1 
Kisii 0 0 63 0 63 
Kisumu 0 0 197 0 197 
Migori 0 0 26 0 26 
Narok 0 0 1 0 1 
Nyamira 0 0 1 0 1 
Siaya 0 0 99 0 99 
Vihiga 0 0 27 0 27 
Trans Nzoia 0 0 0 45 45 
Uasin Gishu 0 0 0 376 376 
West Pokot 0 0 0 17 17 
 1523 597 495 457 3098 
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Table S3. Crude, directly-standardized, population-weighted, and test performance-adjusted SARS-CoV-2 IgG antibody seroprevalence 
estimates by participant characteristics and geography in 8 regions 
 
 
All samples 
Seropositive 
samples Crude seroprevalence 
Kenya population 
(2019 Census) 
Directly standardized 
seroprevalence* 
Bayesian population 
weighted 
seroprevalence** 
Bayesian population 
weighted, test-adjusted 
seroprevalence**  
   % (95% CI)  % (95% CI) % (95% CI) % (95% CI) 
Age            
15 - 24 years 808 49 6.1 4.5 - 7.9 9,733,174 6.3 4.0 - 8.6 5.1 3.7 - 6.9 4.4 2.7 – 6.4 
25 - 34years 1242 66 5.3 4.1 - 6.7 7,424,967 4.3 2.5 - 6.2 4.9 3.6 - 6.4 4.2 2.8 – 6.0 
35 - 44 years 714 50 7.0 5.2 - 9.1 4,909,191 6.3 3.3 - 9.3 5.9 4.3 - 8.1 5.2 3.3 – 7.7 
45 - 54 years 263 9 3.4 1.6 - 6.4 3,094,771 1.3 0.0 - 3.4 3.8 1.9 - 6.0 3.0 1.1 – 5.4 
55 - 64 years 71 0 0  1,988,062 0 0 3.4 0.7 - 6.2 2.9 0.7 – 5.7 
            
Sex            
Male 2540 146 5.7 4.9 - 6.7 13,388,243 4.8 3.9 - 5.7 4.4 2.9 – 6.2 3.6 1.9 – 5.8 
Female 558 28 5.0 3.4 - 7.2 13,761,922 4.6 2.7 - 6.5 5.5 4.4 – 6.8 4.8 3.5 – 6.4 
            
Regions            
Central 105 7 6.7 2.7 - 13.2  3,452,213 5.5 1.2 - 9.9 5.6 2.9 – 10.0 4.9 1.9 – 9.7 
Mombasa 550 51 9.3 7.0 - 12.0 792,072 8.5 6.1 - 10.9 8.3 6.1 – 10.9 7.8 5.4 – 10.8 
Other Coast 973 39 4.0 2.9 - 5.4 1,671,097 2.2 1.0 - 3.4 3.7 2.6 – 5.1 2.9 1.6 – 4.6 
Eastern / N. Eastern 242 11 4.5 2.3 - 8.0 5,176,080 4.4 2.4 - 6.3 4.3 2.5 – 7.0 3.5 1.4 – 6.6 
Nairobi 235 21 8.9 5.6 - 13.3 3,002,314 5.8 2.3 - 9.3 7.6 4.9 – 11.2 7.1 4.2 – 11.2 
Nyanza 442 30 6.8 4.6 - 9.5 3,363,813 6.1 3.8 - 8.4 6.0 4.2 – 8.4 5.2 3.1 – 7.9 
Rift Valley 481 8 1.7 0.7 - 3.3 7,035,581 1.0 0.0 - 2.3 2.1 1.1 – 3.6 1.5 0.4 – 3.1 
Western 70 7 10.0 4.1 - 19.5 2,656,995 11.5 4.4 - 18.7 7.0 3.5 - 13.1 6.3 2.5 – 13.1 
            
Total 3,098 174 5.6 4.8 - 6.5 27,150,165 5.4 4.2 – 6.6 4.9 3.9 –6.2 4.3 2.9 – 5.8 
*Prevalence estimates for regions were directly standardized on age and sex; those for age were directly standardized on sex and region; and those for sex were directly 
standardized on age and region. The total prevalence estimate was directly standardized on age, sex and region.  
**Re-weighted prevalence estimates based on demographic data from the 2019 Kenyan census.
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Table S4. Crude, directly-standardized, population-weighted, and test-performance adjusted SARS-CoV-2 IgG antibody seroprevalence 
estimates by geography in 13 counties/regions 
 
 
County 
All 
samples 
Seropositive 
samples Crude seroprevalence 
Kenya 
population 
(2019 Census) 
Directly standardized 
seroprevalence* 
Bayesian population 
weighted seroprevalence** 
Bayesian population 
weighted, test-adjusted 
seroprevalence**  
    % (95% CI)  % (95% CI) % (95% CI) % (95% CI) 
Region             
Central All 105 7 6.7 2.7 - 13.2 3,452,213 5.5 1.2 - 9.9 5.5 2.7 – 10.0 4.9 1.9 – 9.6 
Coast Kilifi 485 24 4.9 3.2 - 7.3 784,069 2.2 0.3 - 4.2 4.5 2.9 - 6.5 3.9 2.2 – 6.3 
 Kwale 236 12 5.1 2.7 - 8.7 446,434 4.0 0.8 - 7.1 4.5 2.5 - 7.4 3.8 1.6 – 7.0 
 Mombasa 550 51 9.3 7.0 - 12.0 792,072 8.5 6.1 - 10.9 8.3 6.1 - 11.0 8.0 5.5 – 11.1 
 Other 252 3 1.2 0.2 - 3.4 440,594 0.7 0.0 - 2.0 1.9 0.8 - 3.8 1.4 0.4 – 3.4 
Eastern /  Machakos 145 9 6.2 2.9 - 11.4 878,729 7.1 3.6 - 10.5 5.3 2.8 - 9.1 4.6 1.8 – 8.7 
  N Eastern Other 97 2 2.1 0.3 - 7.3 4,297,351 0.8 0.0 - 2.4 2.9 1.0 - 6.3 2.4 0.6 – 5.7 
Nairobi All 235 21 8.9 5.6 - 13.3 3,002,314 5.8 2.3 - 9.3 7.6 4.9 - 11.4 7.3 4.2 – 11.4 
Nyanza Kisumu 197 14 7.1 3.9 - 11.6 657,677 6.3 2.9 - 9.7 6.1 3.6 - 9.7 5.5 2.8 – 9.6 
 Other 245 16 6.5 3.8 - 10.3 2,706,136 5.9 2.4 - 9.4 5.6 3.4 - 8.7 4.9 2.5 – 8.4 
Rift Valley Uasin Gishu 376 3 0.8 0.1 - 2.3 700,908 0.6 0.0 - 1.7 1.5 0.6 - 2.9 1.1 0.3 – 2.6 
 Other 105 5 4.8 1.6 - 10.7 6,334,673 2.7 0.0 - 6.9 4.3 2.0 - 8.3 3.7 1.3 – 8.0 
Western All 70 7 10.0 4.1 - 19.5 2,656,995 11.5 4.4 - 18.7 7.0 3.4 - 13.2 6.4 2.5 – 13.5 
             
Total  3,098 174 5.6 4.8 – 6.5 27,150,165 5.1 3.6 - 6.6 5.2 4.0 – 6.9 4.7 3.2 – 6.5 
*Prevalence estimates for counties were directly standardized on age and sex. The total prevalence estimate was directly standardized on age, sex and region.  
**Re-weighted prevalence estimates based on demographic data from the 2019 Kenyan census.  
 
 
   23  
Table S5. A comparison of the general characteristics and SARS-CoV-2 seroprevalence in the blood donor populations in 
Kenya 
 
 
 
 Family Replacement Donors  Voluntary Non-Remunerated Donors 
 
Number 
sampled 
% of 
sample 
Antibody 
positive 
Seroprevalence 
(%)  
Number 
sampled 
% of 
sample 
Antibody 
positive 
Seroprevalence 
(%) 
All donors 2,862 100.0% 154 5.4%  236 100.0% 20 8.5% 
          
Male 2,346 82.0% 132 5.6%  194 82.2% 14 7.2% 
Female 516 18.0% 22 4.3%  42 17.8% 6 14.3% 
          
15-24 years 755 26.4% 43 5.7%  53 22.5% 6 11.3% 
25-34 years 1,146 40.0% 57 5.0%  96 40.7% 9 9.4% 
35-44 years 663 23.2% 47 7.1%  51 21.6% 3 5.9% 
45-54 years 236 8.2% 7 3.0%  27 11.4% 2 7.4% 
55-64 years 62 2.2% 0 0.0%  9 3.8% 0 0.0% 
